Clinical Trials

Treating & Defeating Cancer: More than 50 Clinical Trials with a Singular Focus

Exelixis engages in research and conducts clinical trials to compile data that can be submitted for review by regulatory authorities, such as the U.S. Food and Drug Administration (FDA). Approval of a medication enables us to commercialize the medication thus making it available to a larger number of patients in need of treatment. Trials for cabozantinib include Exelixis-sponsored trials, as well as National Cancer Institute and investigator-sponsored trials.

Exelixis-sponsored Clinical Trials

Ongoing Exelixis-sponsored global, randomized phase 3 pivotal trials of cabozantinib include the:

  • METEOR study in advanced renal cell carcinoma (RCC)
  • CELESTIAL study in advanced hepatocellular cancer
  • CheckMate 9ER trial, in partnership with Bristol-Myers Squibb Company, looking at CABOMETYX® in combination with Opdivo® and/or Yervoy® for previously untreated, advanced or metastatic RCC.

You can access a detailed list of cabozantinib clinical studies posted on www.ClinicalTrials.gov. For further information regarding all clinical trials, please contact Exelixis Medical Information at 1-888-EXELIXIS (1-888-393-5494) or at druginfo@exelixis.com.

National Cancer Institute-sponsored Trials

In November 2011, Exelixis entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute’s Cancer Therapy Evaluation Program (NCI-CTEP). The CRADA reflects a commitment by NCI-CTEP to support the investigation of cabozantinib’s potential in a wide variety of cancers, providing for the initiation of as many as 20 active clinical trials each year for a five-year period. As such, this agreement enables us to expand the cabozantinib development program by substantially increasing the number of indications and disease settings in which it is being investigated.

You can access a detailed list of cabozantinib clinical studies, including NCI-CTEP trials, at www.ClinicalTrials.gov. For further information regarding all clinical trials, please contact Exelixis Medical Information at 1-888-EXELIXIS (1-888-393-5494) or at druginfo@exelixis.com.

Investigator-sponsored Trials

Cabozantinib is also being evaluated in a variety of investigator sponsored trials (ISTs). You can access a detailed list of cabozantinib clinical studies, including ISTs, at www.ClinicalTrials.gov. For further information regarding all clinical trials, please contact Exelixis Medical Information at 1-888-EXELIXIS (1-888-393-5494) or at druginfo@exelixis.com.

Clinical Trial FAQ

Please see below for answers to some frequently asked questions about our clinical trials.

I am a patient who is interested in getting on a trial with cabozantinib. How do I find out more information?

Please speak to your physician to determine if participation in a cabozantinib clinical trial may be appropriate for you. You may visit www.ClinicalTrials.gov or contact Exelixis Medical Information at 1-888-EXELIXIS (1-888-393-5494) to find a clinical trial site in your area. You will need to speak to someone at a clinical trial site in order to determine if you can be enrolled in the trial.

I am a health care practitioner who wants to put one of my patients on a cabozantinib trial. What steps do I need to take?

Please visit www.ClinicalTrials.gov or contact Exelixis Medical Information at 1-888-EXELIXIS (1-888-393-5494) or at druginfo@exelixis.com to find a clinical trial site in your area.

I am an investigator interested in participating in clinical trials with cabozantinib. Who do I contact?

Please contact Exelixis Medical Information at 1-888-EXELIXIS (1-888-393-5494) or at druginfo@exelixis.com for information about participating as an investigator in cabozantinib clinical trials.

Other Questions?

For all other questions regarding clinical trials please contact Exelixis Medical Information at 1-888-EXELIXIS (1-888-393-5494) or at druginfo@exelixis.com.

Cancer is our Cause

At Exelixis, we are on a mission to transform cancer treatment.

Learn More